Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Haemonetics (HAE) over the last 12 years, with Q4 2025 value amounting to $9.3 million.

  • Haemonetics' Asset Writedowns and Impairment changed N/A to $9.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $17.9 million, marking a year-over-year increase of 338927.88%. This contributed to the annual value of $2.4 million for FY2025, which is 7705.15% down from last year.
  • Haemonetics' Asset Writedowns and Impairment amounted to $9.3 million in Q4 2025.
  • Haemonetics' Asset Writedowns and Impairment's 5-year high stood at $20.9 million during Q2 2021, with a 5-year trough of $94000.0 in Q3 2022.
  • In the last 4 years, Haemonetics' Asset Writedowns and Impairment had a median value of $5.1 million in 2021 and averaged $6.8 million.
  • Per our database at Business Quant, Haemonetics' Asset Writedowns and Impairment soared by 104695000.0% in 2021 and then tumbled by 9817.26% in 2022.
  • Over the past 4 years, Haemonetics' Asset Writedowns and Impairment (Quarter) stood at $5.1 million in 2021, then tumbled by 98.17% to $94000.0 in 2022, then soared by 445.74% to $513000.0 in 2023, then skyrocketed by 1712.87% to $9.3 million in 2025.
  • Its Asset Writedowns and Impairment was $9.3 million in Q4 2025, compared to $8.6 million in Q3 2025 and $513000.0 in Q2 2023.